Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

IBIO

iBio Inc

Feb 13 • 04:00PM ET

2.22

+0.11 5.21 %

Healthcare • Biotechnology • USA • NASD

Peers: NVAX ARCT INO CODX OCGN VXRT ADMA IBRX ALT APRE

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-1.01	Insider Own	12.38%	Shs Outstand	30.05M	Perf Week	-8.26%
Market Cap	76.69M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	0.00%	Shs Float	20.85M	Perf Month	-10.84%
Enterprise Value	26.44M	PEG	-	EPS next Q	-0.06	Inst Own	62.38%	Short Float	18.48%	Perf Quarter	77.60%
Income	-24.74M	P/S	255.63	EPS this Y	83.43%	Inst Trans	19.17%	Short Ratio	0.67	Perf Half Y	227.43%
Sales	0.30M	P/B	1.18	EPS next Y	3.45%	ROA	-57.47%	Short Interest	3.85M	Perf YTD	15.03%
Book/sh	1.88	P/C	1.46	EPS next 5Y	39.89%	ROE	-70.22%	52W High	6.89 -67.78%	Perf Year	-38.33%
Cash/sh	1.53	P/FCF	-	EPS past 3/5Y	91.54% 64.37%	ROIC	-42.29%	52W Low	0.56 299.14%	Perf 3Y	-88.29%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-40.34% -24.57%	Gross Margin	-265.67%	Volatility	9.97% 9.78%	Perf 5Y	-99.82%
Dividend TTM	-	EV/Sales	88.13	EPS Y/Y TTM	62.69%	Oper. Margin	-7657.67%	ATR (14)	0.24	Perf 10Y	-99.92%
Dividend Ex-Date	-	Quick Ratio	9.04	Sales Y/Y TTM	-20.00%	Profit Margin	-8245.67%	RSI (14)	50.90	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.04	EPS Q/Q	81.02%	SMA20	-0.80%	Beta	1.24	Target Price	5.25
Payout	-	Debt/Eq	0.04	Sales Q/Q	-100.00%	SMA50	5.47%	Rel Volume	0.13	Prev Close	2.11
Employees	20	LT Debt/Eq	0.03	Earnings	Feb 10 AMC	SMA200	85.06%	Avg Volume	5.75M	Price	2.22
IPO	Aug 19, 2008	Option/Short	No / Yes	EPS/Sales Surpr.	35.71% -100.00%	Trades		Volume	721,002	Change	5.21%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Oppenheimer	Outperform	$5
Oct-17-25	Initiated	Leerink Partners	Outperform	$2
May-28-24	Initiated	Chardan Capital Markets	Buy	$5
Nov-29-21	Initiated	JMP Securities	Mkt Outperform	$1.50
Jan-22-21	Initiated	Cantor Fitzgerald	Overweight	$3
Jun-26-20	Initiated	Alliance Global Partners	Buy	$2.55

Feb-10-26 04:05PM	iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -5.81%
Feb-03-26 10:00AM	CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-02-26 10:00AM	iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks) +9.52%
Jan-09-26 07:00AM	iBio Announces $26 Million Private Placement (GlobeNewswire) +14.89%
Nov-24-25 04:15PM	iBio to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire) +5.71% +5.41%
05:15PM	Loading…
Nov-12-25 05:15PM	iBio, Inc. (IBIO) Reports Q1 Loss (Zacks) -8.00%
04:01PM	iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-30-25 07:00AM	iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance (GlobeNewswire)
Oct-23-25 07:00AM	iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire) -8.63%
Oct-21-25 07:00AM	iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek and PEGS Europe 2025 (GlobeNewswire) +24.30%
Sep-05-25 07:30AM	iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-25-25 07:00AM	iBio Announces Closing of $50 Million Public Offering (GlobeNewswire) +6.93%
Aug-19-25 08:01AM	iBio Announces Pricing of $50 Million Public Offering (GlobeNewswire)
Aug-18-25 04:01PM	iBio Announces Proposed Public Offering (GlobeNewswire)
Jun-24-25 07:00AM	iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results (GlobeNewswire)
04:15PM	Loading…
Jun-23-25 04:15PM	iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call (GlobeNewswire) -7.60%
Jun-16-25 07:00AM	iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment (GlobeNewswire) -5.83%
May-05-25 08:00AM	iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model (GlobeNewswire)
May-02-25 08:00AM	iBio Reports Fiscal Third Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 01:43PM	iBio Raises $6.2 Million Through Warrant Inducement Transaction (GlobeNewswire)
Apr-22-25 08:00AM	iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio (GlobeNewswire) -17.43%
Apr-07-25 07:00AM	iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline (GlobeNewswire) -53.18%
Apr-01-25 10:00AM	iBio, Inc. Common Stock (IBIO): Among Stocks Insiders Were Buying In Q1 2025 (Insider Monkey)
Feb-19-25 04:05PM	iBio to Begin Trading on the Nasdaq Stock Exchange (GlobeNewswire) -5.71%
Feb-17-25 04:38PM	Is Ibio, Inc. (IBIO) Among Stocks Insiders Are Buying This Year? (Insider Monkey)
Feb-10-25 04:05PM	iBio Reports Fiscal Second Quarter 2025 Financial Results (GlobeNewswire) -8.06% -7.31%
Jan-13-25 07:00AM	iBio Announces New Investments from Board Members and Officers (GlobeNewswire)
Jan-07-25 07:00AM	iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio (GlobeNewswire) +10.16%
Jan-03-25 07:58AM	iBio Expands Pipeline with New Antibody Agreement (TipRanks)
Jan-02-25 09:24AM	Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform (Benzinga)
07:00AM	Loading…
07:00AM	iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio (GlobeNewswire)
Nov-25-24 08:00AM	iBio Strengthens Board with Appointment of Two New Independent Directors (GlobeNewswire)
Nov-12-24 04:05PM	iBio Reports Fiscal First Quarter 2025 Financial Results (GlobeNewswire) -9.02%
Oct-10-24 08:00AM	iBio and AstralBio Provide Update on Myostatin Program for Obesity (GlobeNewswire) -7.75%
Sep-20-24 04:05PM	iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.09%
Sep-03-24 07:00AM	iBio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 04:30PM	iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development (GlobeNewswire) +23.42%
Jun-03-24 07:00AM	iBio Closes Sale of Manufacturing Facility in Texas (GlobeNewswire)
May-13-24 04:05PM	iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-05-24 02:35PM	3 Healthcare Stocks Short Sellers Are Prescribing for Trouble (InvestorPlace) -15.26%
Mar-27-24 07:00AM	iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases (GlobeNewswire) +192.17%
Mar-26-24 07:35PM	iBio Announces $15.0 Million Private Placement (GlobeNewswire) +5.02%
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Feb-26-24 07:45AM	iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka (GlobeNewswire)
Jan-16-24 08:15AM	iBio Announces Participation in 23rd Annual PepTalk Conference (GlobeNewswire)
Dec-26-23 07:15AM	iBio Amends and Extends Maturity of Credit Agreement (GlobeNewswire)
Dec-05-23 08:00AM	iBio, Inc. Announces Pricing of $4.5 Million Public Offering (GlobeNewswire) -50.00%
Nov-27-23 05:20PM	iBio Announces Reverse Stock Split (GlobeNewswire) -31.03%
Nov-01-23 08:24AM	iBio Further Expands Tech Stack with ShieldTx; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific (GlobeNewswire)
Oct-10-23 08:00AM	iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics (GlobeNewswire) +7.14%
Oct-02-23 06:45AM	iBio Explains Recent Filing of Registration Statement (GlobeNewswire)
Sep-27-23 04:19PM	iBio Announces Filing of 2023 Annual Report on SEC Form 10-K (GlobeNewswire)
Sep-21-23 04:05PM	iBio Announces Amendment to Credit Agreement with Woodforest (GlobeNewswire)
Aug-14-23 04:15PM	iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development (GlobeNewswire) -6.53%
Jun-27-23 08:00AM	iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Companys Next Stage of Growth (GlobeNewswire) -7.38%
Jun-20-23 08:25AM	3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever (InvestorPlace)
Jun-12-23 04:15PM	iBio Forges Research Collaboration with the National Institutes of Health (GlobeNewswire)
Jun-06-23 08:00AM	iBio Expands Tech Stack with EngageTx; Adds TROP-2 Bispecific to Development Pipeline (GlobeNewswire) +9.25%
May-09-23 04:30PM	iBio to Participate in the JMP Securities Life Sciences Conference (GlobeNewswire)
Apr-04-23 04:05PM	iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform (GlobeNewswire) -12.35% -18.12%
Mar-31-23 08:10AM	iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing (GlobeNewswire)
Feb-16-23 04:48PM	iBio Announces MUC16 as its Latest Immune-Oncology Target Program (GlobeNewswire) -11.86% +97.28%
Jan-05-23 08:00AM	iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine (GlobeNewswire) -5.23%
Dec-09-22 04:05PM	iBio Announces Closing of $3.5 Million Underwritten Public Offering (GlobeNewswire) -7.16%
Dec-06-22 11:27PM	iBio Announces Pricing of $3.5 Million Underwritten Public Offering (GlobeNewswire) -57.88%
04:01PM	iBio Announces Proposed Underwritten Public Offering (GlobeNewswire)
08:00AM	iBio to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Dec-05-22 08:00AM	iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022 (GlobeNewswire)
Dec-02-22 04:30PM	iBio Announces CEO Departure (GlobeNewswire) +6.25%
Nov-03-22 08:00AM	iBio Accelerates Transformation to AI-Powered Biotech (GlobeNewswire) -9.71%
Oct-27-22 06:40PM	7 Penny Stocks to Sell Pronto Before a Painful Downturn (InvestorPlace) -5.14%
Sep-30-22 11:48AM	3 Healthcare Stocks to Sell Before They Die (InvestorPlace) -6.53%
Sep-27-22 04:30PM	Edited Transcript of IBIO.A earnings conference call or presentation 27-Sep-22 8:30pm GMT (Thomson Reuters StreetEvents) -32.28%
04:10PM	iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-21-22 08:30AM	iBio Acquires RubrYc Therapeutics AI Drug Discovery Platform and Pipeline (GlobeNewswire) +12.18%
Aug-16-22 09:00AM	iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate (GlobeNewswire)
May-18-22 08:00AM	iBio to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire) -7.55%
May-16-22 10:25AM	iBio (IBIO) Q3 2022 Earnings Call Transcript (Motley Fool)
May-12-22 04:05PM	iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +10.12% -7.00%
May-09-22 08:00AM	iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer (GlobeNewswire)
May-05-22 04:30PM	iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022 (GlobeNewswire) -8.38%
May-02-22 08:00AM	iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants (GlobeNewswire)
Mar-11-22 08:00AM	iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Feb-14-22 04:05PM	iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-07-22 04:30PM	iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022 (GlobeNewswire)
Jan-26-22 11:21AM	iBio Advances Its Vaccine Program for Multi-Variant COVID-19 Disease (Benzinga)
09:00AM	iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease (GlobeNewswire)
Jan-04-22 04:30PM	iBio Announces Participation in the H.C. Wainwright BioConnect Conference (GlobeNewswire) -6.78%
Dec-22-21 09:25AM	iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022 (GlobeNewswire)
Dec-21-21 09:20AM	iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting (GlobeNewswire)
Dec-10-21 08:30AM	iBio Announces Partial Adjournment of Annual Meeting to December 22 (GlobeNewswire)
Nov-30-21 11:57AM	10 Biotech Penny Stocks to Buy Now (Insider Monkey) -12.73%
08:00AM	ISS Joins Glass Lewis in Recommending Shareholders Vote FOR All Proposals Ahead of iBios Upcoming Annual Meeting (GlobeNewswire)
Nov-29-21 08:45AM	Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202 (GlobeNewswire) +29.15%
Nov-17-21 04:30PM	Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote FOR All Proposals Ahead of Annual Meeting (GlobeNewswire) -6.08%
Nov-15-21 04:05PM	iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -7.97%
01:00PM	iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors (GlobeNewswire)
Nov-08-21 04:30PM	iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021 (GlobeNewswire)
Nov-03-21 04:47PM	iBio Acquires FastPharming Manufacturing Facility® (GlobeNewswire) +9.08%
Oct-26-21 08:35AM	iBio Urges Shareholders to Vote FOR All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9 (GlobeNewswire)

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

Open in Screener

MCRB

Seres Therapeutics Inc

Feb 13 • 04:00PM ET

8.47

+0.25 3.04 %

Healthcare • Biotechnology • USA • NASD

MCRB Seres Therapeutics Inc daily Stock Chart

Peers: CRSP FATE NTLA BPMC SANA EDIT BLUE ADPT XBIO CLRB

| Held by: VTI VXF AVUV SCHA IWC PRFZ EES AVSC BTEC AVUS

Index	-	P/E	13.95	EPS (ttm)	0.61	Insider Own	25.86%	Shs Outstand	8.76M	Perf Week	-39.33%
Market Cap	76.62M	Forward P/E	-	EPS next Y	-7.82	Insider Trans	-0.13%	Shs Float	6.71M	Perf Month	-47.33%
Enterprise Value	114.23M	PEG	-	EPS next Q	-2.11	Inst Own	11.45%	Short Float	12.32%	Perf Quarter	-47.10%
Income	5.39M	P/S	218.91	EPS this Y	-	Inst Trans	-1.88%	Short Ratio	5.36	Perf Half Y	-49.76%
Sales	0.35M	P/B	1.70	EPS next Y	-3069.62%	ROA	3.35%	Short Interest	0.83M	Perf YTD	-43.08%
Book/sh	4.99	P/C	1.61	EPS next 5Y	-	ROE	15.95%	52W High	29.98 -71.75%	Perf Year	-49.58%
Cash/sh	5.27	P/FCF	-	EPS past 3/5Y	-9.67% 5.33%	ROIC	4.53%	52W Low	6.53 29.71%	Perf 3Y	-92.14%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-1686.61%	Volatility	14.69% 8.50%	Perf 5Y	-98.37%
Dividend TTM	-	EV/Sales	326.37	EPS Y/Y TTM	102.58%	Oper. Margin	-29466.95%	ATR (14)	1.38	Perf 10Y	-98.36%
Dividend Ex-Date	-	Quick Ratio	2.30	Sales Y/Y TTM	448.44%	Profit Margin	1536.75%	RSI (14)	23.31	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	2.30	EPS Q/Q	112.32%	SMA20	-40.39%	Beta	0.35	Target Price	21.00
Payout	-	Debt/Eq	1.95	Sales Q/Q	-	SMA50	-44.19%	Rel Volume	2.04	Prev Close	8.22
Employees	103	LT Debt/Eq	1.72	Earnings	Nov 05 BMO	SMA200	-41.83%	Avg Volume	154.30K	Price	8.47
IPO	Jun 26, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	105.82% -95.52%	Trades		Volume	315,488	Change	3.04%

Date	Action	Analyst	Rating Change	Price Target Change
May-08-25	Downgrade	Chardan Capital Markets	Buy → Neutral	$6
Oct-24-24	Downgrade	JP Morgan	Neutral → Underweight
Jun-26-23	Resumed	Oppenheimer	Outperform	$12
Apr-21-23	Initiated	JP Morgan	Neutral	$7
Jul-23-21	Downgrade	Goldman	Neutral → Sell	$24 → $7
May-18-21	Resumed	Goldman	Neutral	$24
Mar-05-21	Upgrade	Chardan Capital Markets	Neutral → Buy	$30
Sep-18-20	Downgrade	Chardan Capital Markets	Buy → Neutral	$32.50 → $27.50
Aug-18-20	Initiated	Piper Sandler	Overweight	$40
Aug-11-20	Upgrade	Jefferies	Hold → Buy	$4 → $29
Aug-11-20	Reiterated	H.C. Wainwright	Buy	$8 → $41
Apr-30-19	Initiated	Jefferies	Hold	$7
Oct-22-18	Initiated	Chardan Capital Markets	Buy	$15
Oct-13-17	Initiated	Oppenheimer	Outperform	$19
Aug-04-17	Reiterated	H.C. Wainwright	Buy	$15 → $19
Feb-01-17	Reiterated	FBR & Co.	Outperform	$23 → $18
Aug-12-16	Reiterated	FBR Capital	Outperform	$43 → $23
Aug-01-16	Reiterated	H.C. Wainwright	Buy	$50 → $15
Aug-01-16	Downgrade	BofA/Merrill	Buy → Neutral
Jul-29-16	Resumed	H.C. Wainwright	Buy	$50

Show Previous Ratings

Feb-12-26 08:29AM	Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash (Benzinga) -41.66%
07:00AM	Seres to lay off staff, pause top program in latest reboot (BioPharma Dive)
07:00AM	Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases (GlobeNewswire)
Jan-06-26 07:00AM	Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy (GlobeNewswire)
Dec-29-25 10:15AM	3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround (Zacks)
07:00AM	Loading…
Nov-24-25 07:00AM	Seres Therapeutics to Participate in Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-05-25 07:00AM	Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -7.64%
Oct-30-25 07:00AM	Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 (GlobeNewswire) -6.57%
Oct-29-25 07:00AM	Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 (GlobeNewswire)
Oct-14-25 07:00AM	Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (GlobeNewswire)
Sep-23-25 07:00AM	Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway (GlobeNewswire) +6.30%
Sep-09-25 12:00PM	All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy (Zacks) -18.40%
Aug-28-25 09:55AM	Seres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Aug-27-25 07:00AM	Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-06-25 07:30AM	Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share (BioPharma Dive)
07:15AM	Loading…
07:15AM	Seres Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-22-25 07:01AM	Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 (GlobeNewswire) -10.54%
07:00AM	Seres Therapeutics Announces Leadership Transition (GlobeNewswire)
Jun-19-25 10:16AM	Human Microbiome Market Forecasts Report 2025-2030: Key Insights for Navigating Emerging Opportunities (GlobeNewswire)
May-27-25 07:00AM	Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting (GlobeNewswire) -5.74%
May-23-25 12:00PM	Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-16-25 09:55AM	Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade (Zacks)
May-07-25 02:18PM	Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:17AM	Seres Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-29-25 07:00AM	Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases (GlobeNewswire)
Apr-23-25 07:00AM	Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 (GlobeNewswire) +19.24%
Apr-17-25 09:35AM	Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround (Zacks) -7.48%
Mar-14-25 03:04AM	Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ... (GuruFocus.com) +8.05%
02:23AM	Loading…
02:23AM	Q4 2024 Seres Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-25 07:00AM	Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire) -7.91%
Mar-04-25 07:00AM	Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025 (GlobeNewswire) -10.50%
Mar-03-25 07:00AM	Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach (GlobeNewswire)
Jan-16-25 07:00AM	Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale (GlobeNewswire) -5.77%
Jan-10-25 07:15AM	Seres announces new translational biomarker results from SER-155 Phase 1b study (TipRanks)
Jan-09-25 07:00AM	Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates (GlobeNewswire)
Dec-17-24 07:30AM	Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference (TipRanks)
Dec-16-24 07:00AM	Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-24 05:43AM	Seres SER-155 gains breakthrough status for BSIs reduction (Pharmaceutical Technology) +9.20%
Dec-09-24 07:00AM	FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) (GlobeNewswire)
Nov-22-24 07:00AM	Seres Therapeutics to Participate in Piper Sandler Healthcare Conference (GlobeNewswire) +5.03%
Nov-14-24 02:08AM	Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... (GuruFocus.com)
Nov-13-24 07:23AM	Seres Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -11.10%
07:00AM	Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-24 07:00AM	Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 (GlobeNewswire) -6.98%
Sep-30-24 05:15PM	Seres Therapeutics Announces Completion of VOWST Asset Sale to Societe des Produits Nestle S.A (GlobeNewswire)
05:15PM	Seres Therapeutics Announces Completion of VOWST Asset Sale to Soci t des Produits Nestl S.A (GlobeNewswire)
Sep-27-24 03:26PM	Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestle (Business Wire) +10.44%
Sep-26-24 04:01PM	Seres Therapeutics Stockholders Approve Sale of VOWST to Nestle Health Science; Sale Expected to Close on September 30 (GlobeNewswire) -9.10%
04:01PM	Seres Therapeutics Stockholders Approve Sale of VOWST to Nestl Health Science; Sale Expected to Close on September 30 (GlobeNewswire)
Sep-13-24 07:00AM	Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference (GlobeNewswire)
Sep-12-24 07:00AM	Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) (GlobeNewswire) -8.57%
Sep-04-24 09:35AM	After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB) (Zacks)
Aug-15-24 09:55AM	Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now (Zacks)
Aug-14-24 03:09AM	Q2 2024 Seres Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.07%
Aug-13-24 07:15AM	Seres Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -6.97%
07:00AM	Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-06-24 07:00AM	Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024 (GlobeNewswire) -21.09%
07:00AM	Seres Therapeutics Announces Signing of VOWST Asset Purchase Agreement with Nestle Health Science (GlobeNewswire)
07:00AM	Seres Therapeutics Announces Signing of VOWST Asset Purchase Agreement with Nestl Health Science (GlobeNewswire)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire) -6.18%
Jun-07-24 04:00PM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -28.03% +20.54%
Jun-06-24 07:05AM	Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle (BioPharma Dive) -25.17%
07:00AM	Nestl Health Science agrees to acquire global rights to VOWST, product it launched in June 2023 (PR Newswire)
06:30AM	Seres Therapeutics Enters Into Memorandum of Understanding For Vowst Asset Sale to Nestle Health Science (GlobeNewswire)
06:30AM	Seres Therapeutics Enters Into Memorandum of Understanding For Vowst Asset Sale to Nestl Health Science (GlobeNewswire)
May-13-24 12:18PM	Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.38%
May-09-24 11:06AM	Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating (MT Newswires) +37.44%
07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire)
06:30AM	Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating (MT Newswires)
03:11AM	Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... (GuruFocus.com)
May-08-24 11:54AM	MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -32.49%
08:42AM	Seres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue Estimates (GuruFocus.com)
07:25AM	Seres Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
May-06-24 04:01PM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.72%
09:30AM	Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024 (Business Wire)
Apr-09-24 07:00AM	Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT (Business Wire)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Mar-28-24 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-19-24 08:30AM	Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (PR Newswire) +6.34%
07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-13-24 03:32PM	11 Oversold NASDAQ Stocks To Buy Right Now (Insider Monkey)
08:17AM	11 Oversold Healthcare Stocks To Buy Right Now (Insider Monkey)
Mar-07-24 11:48AM	Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 02:17AM	Q4 2023 Seres Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-05-24 09:51AM	MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -7.02%
07:32AM	Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023 (GuruFocus.com)
07:00AM	Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (Business Wire)
Feb-28-24 07:00AM	Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024 (Business Wire)
Feb-27-24 07:00AM	Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference (Business Wire) +6.54%
Feb-26-24 07:00AM	Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz (Business Wire)
Jan-17-24 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-09-24 08:44AM	DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING (PR Newswire) -8.33%
07:00AM	Seres Therapeutics Announces VOWST Commercial Launch Update and US FDA Fast Track Designation for SER-155 (Business Wire)
Jan-08-24 06:30AM	Flagship Pioneering Debuts Enabling Technologies Initiative (PR Newswire) +11.43%
06:30AM	Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine (PR Newswire)
Jan-04-24 04:00PM	Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +5.26%
Dec-07-23 07:46PM	Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023 (Business Wire)

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Young Teresa L.	See Remarks	Nov 15 '25	Sale	17.30	1,042	18,027	8,401	Nov 18 04:30 PM
Shaff Eric D.	Director	Nov 15 '25	Sale	17.30	217	3,754	11,113	Nov 18 04:30 PM
DesRosier Thomas	See Remarks	Nov 15 '25	Sale	17.30	76	1,315	7,623	Nov 18 04:30 PM
Henn Matthew R	See Remarks	Nov 15 '25	Sale	17.30	1,257	21,746	7,527	Nov 18 04:30 PM
Shaff Eric D.	Director	Aug 18 '25	Sale	16.65	217	3,613	10,609	Aug 19 04:08 PM
DesRosier Thomas	See Remarks	Aug 18 '25	Sale	16.65	76	1,265	7,455	Aug 19 04:07 PM
Henn Matthew R	See Remarks	Aug 18 '25	Sale	16.65	73	1,215	4,548	Aug 19 04:07 PM
Young Teresa L.	See Remarks	Aug 18 '25	Sale	16.65	59	982	5,215	Aug 19 04:06 PM
Young Teresa L.	See Remarks	May 16 '25	Sale	7.28	63	459	5,044	May 19 04:05 PM
Shaff Eric D.	CEO and President	May 16 '25	Sale	7.28	220	1,602	10,102	May 19 04:05 PM
DesRosier Thomas	Chief Legal Officer and EVP	May 15 '25	Sale	7.28	79	575	7,287	May 19 04:05 PM
Henn Matthew R	See Remarks	May 16 '25	Sale	7.28	77	561	4,383	May 19 04:05 PM
Young Teresa L.	See Remarks	Feb 18 '25	Sale	0.81	3,338	2,704	97,536	Feb 19 08:11 PM
Henn Matthew R.	See Remarks	Feb 18 '25	Sale	0.81	3,953	3,204	84,443	Feb 19 08:10 PM
Shaff Eric D.	CEO and President	Feb 18 '25	Sale	0.81	12,726	10,314	192,039	Feb 19 08:08 PM
DesRosier Thomas	Chief Legal Officer and EVP	Feb 18 '25	Sale	0.81	4,300	3,485	142,456	Feb 19 08:07 PM
von Moltke Lisa	See Remarks	Feb 18 '25	Sale	0.81	4,416	3,579	39,875	Feb 19 08:05 PM

IBIO

iBio Inc

MCRB

Seres Therapeutics Inc

Upgrade your FINVIZ experience